- Ferring launches a new company FerGene focusing the global development and commercialization of Nadofaragene firadenovec in the US for the patients with Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer
- Blackstone to invest $400M and its expertise to accelerate the future development and commercialization of Nadofaragene firadenovec while Ferring will invest up to $170M and will get MAA for the therapy if approved by the US FDA.
- Nadofaragene firadenovec is an adenovirally mediated interferon alfa-2b gene therapy being developed in P-III study as a treatment for patients with high-grade, BCG unresponsive, NMIBC and has received FDA’s PR & BT designation. The US FDA has accepted BLA filing for Nadofaragene firadenovec
Click here to read full press release/ article | Ref: Blackstone | Image: VC Circle